At a glance
- Originator Nippon Soda
- Developer Banyu; Nippon Soda
- Class Antithrombotics; Pyridazines
- Mechanism of Action Type 3 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 12 Feb 2008 Discontinued - Preclinical for Thrombosis in Japan (unspecified route)
- 31 Mar 2004 Banyu Pharmaceutical has become a wholly owned subsidiary of Merck & Co
- 16 May 2000 Preclinical development for Thrombosis in Japan (unspecified route)